Allon Therapeutics Inc NPCUF

Healthcare Biotechnology

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).

GREY:NPCUF - Post by User

Allon Therapeutics Inc

Bullboard Posts

Comment by diadon1945on Dec 15, 2012 2:17pm

348 Views

Post# 20735530

RE: RE: RE: RE: : Allon Raising $50 Million

It is interesting to compare NPC to ONCY. ONCY announced some good results from an interim analysis of a phase III trial for it's drug which has a revenue potential estimated at between $900 million and $3 billion. The share price went up as high as $3.75 with a $9 target.

Allon is going after PSP as part of the $3-4 billion frontotemperal dementia market as the first indication.PSP potential revenue alone is over $700 million. But they have also done a phase 1 in Parkinsons,and a phase 2a in both Alzheimers and Schizophrenia. All together these could be another $20-30 billion. It is hard to estimate the market size because up to this point most treatments have only dealt with symptoms and not the underlying pathology the way Davunitide does.

If ONCY is worth $3.75 per share for interim phase III results and a high revenue estimate of $3 billion what is NPC worth if it has successful FINAL phase III trial results in PSP and potential in indications with market value exceeding $30 billion?

Bullboard Posts

Dynamic Funds Launches new ETF series on the TSX